Systemic and Topical Treatments for Autoimmune Bullous Disease: A Network Meta-Analysis of Randomized Controlled Trials

0
0
0

Systemic and Topical Treatments for Autoimmune Bullous Disease: A Network Meta-Analysis of Randomized Controlled Trials

Autoimmune bullous diseases (AIBDs) represent a heterogeneous group of disorders characterized by blistering of the skin and mucous membranes due to autoantibody-mediated disruption of structural proteins. These conditions are broadly categorized into pemphigus and pemphigoid diseases. Pemphigus vulgaris (PV), the most common intraepidermal AIBD, primarily affects individuals aged 40–60 years, while bullous pemphigoid (BP), the predominant subepidermal AIBD, shows increasing incidence in elderly populations. The clinical management of AIBDs involves systemic and topical therapies aimed at controlling disease activity, reducing relapse rates, and minimizing treatment-related adverse effects. However, the comparative effectiveness of these therapies remains unclear. This network meta-analysis (NMA) synthesizes evidence from randomized controlled trials (RCTs) to evaluate the efficacy and safety of various treatment modalities for AIBDs, providing a hierarchical ranking of interventions to guide clinical decision-making.

Study Design and Methodology

The analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-NMA guidelines and was registered with PROSPERO (CRD42023487905). The PICO framework structured the research question:

  • Population: Patients diagnosed with AIBDs.
  • Interventions: Any systemic or topical treatment for AIBDs.
  • Comparators: Other treatments, placebo, or no treatment.
  • Outcomes: Primary outcome—complete remission rate; secondary outcomes—recurrence rate, cumulative glucocorticoid dose until disease control, and adverse event rate.

A comprehensive search of Medline, EMBASE, and Cochrane databases was conducted through May 31, 2023, with an updated search in October 2023. Manual reviews of reference lists and clinical trial registries supplemented the electronic search. Inclusion criteria required RCTs evaluating AIBD treatments in English-language journals, while quasi-randomized studies, abstracts, and trials lacking predefined outcomes were excluded.

From 12,580 initially identified records, 29 RCTs involving 1,817 patients were included in the final analysis. These comprised 22 studies on pemphigus (1,173 patients) and 7 on pemphigoid (644 patients). The interventions evaluated included systemic corticosteroids, rituximab (RTX), azathioprine (AZA), mycophenolate mofetil (MMF), cyclophosphamide (CTX), doxycycline (DOX), intravenous immunoglobulin (IVIG), and topical therapies such as clobetasol propionate.

Key Findings

Complete Remission Rate

The NMA evaluated 20 interventions across 29 studies (2,013 patients). Oral corticosteroids (prednisolone/methylprednisolone) combined with full-dose rituximab (1,000 mg administered twice, two weeks apart) (P-full RTX) demonstrated the highest complete remission rate (SUCRA: 94.8%). This regimen significantly outperformed other therapies:

  • P-full RTX vs. P-IVIG: Odds ratio (OR) 4.40 (95% CI: 1.47–13.21).
  • P-full RTX vs. P-AZA: OR 7.34 (3.38–15.93).
  • P-full RTX vs. P-MMF: OR 8.77 (4.71–16.34).

Topical corticosteroids combined with oral steroids (P-TCPR) ranked second (SUCRA: 89.1%), followed by low-dose RTX (500 mg; SUCRA: 83.8%) and IVIG (74.3%). Pulse steroid-cyclophosphamide therapy (D/M-CPT) and DOX monotherapy ranked lowest (SUCRA: 18.2% and 12.8%, respectively).

Cumulative Glucocorticoid Dose

Nineteen studies (1,068 patients) assessed cumulative steroid doses required for disease control. P-full RTX again ranked highest (SUCRA: 74.1%), followed by MMF (72.6%) and low-dose RTX (66.9%). AZA-based regimens required higher steroid doses (SUCRA: 27.2%). No significant differences were observed between interventions, suggesting comparable steroid-sparing effects among higher-ranked therapies.

Recurrence Rate

Analysis of 19 studies (1,349 patients) revealed P-full RTX as the most effective in preventing relapse (SUCRA: 87.5%). It significantly reduced recurrence compared to AZA (OR: 0.26; 0.08–0.84), DOX (OR: 0.22; 0.07–0.71), and MMF (OR: 0.10; 0.04–0.24). Pulse cyclophosphamide with pentoxifylline (D/M-CPT-PTX) showed the lowest recurrence risk (SUCRA: 94.1%), though its application was limited to specific trial designs.

Adverse Event Rates

Seventeen studies (1,329 patients) evaluated safety profiles. P-full RTX and infliximab (P-IFX) exhibited the lowest adverse event rates (SUCRA: 87.7% and 87.6%, respectively). DOX monotherapy ranked third (79.6%), while AZA combined with pulse dexamethasone (P-AZA-DPT) had the highest adverse events (SUCRA: 4.7%).

Clinical Implications

The findings underscore rituximab’s superiority in AIBD management, particularly when administered at full doses (1,000 mg). Its efficacy in achieving remission, reducing relapse, and minimizing steroid dependence aligns with current guidelines recommending RTX as first-line therapy for moderate-to-severe pemphigus. The analysis also highlights the utility of topical corticosteroids as an adjunct to systemic therapy, offering high remission rates with localized action.

While MMF and AZA remain viable steroid-sparing agents, MMF’s favorable safety profile positions it as a preferable initial adjuvant. In contrast, pulse cyclophosphamide regimens, though effective in reducing recurrence, warrant caution due to higher toxicity risks. Doxycycline, though less effective in monotherapy, may serve as a niche option for elderly BP patients with contraindications to immunosuppressants.

Limitations and Future Directions

The study’s conclusions are tempered by heterogeneity in trial designs, varying outcome definitions, and the predominance of small-sample RCTs. Publication bias and incomplete reporting of long-term outcomes further limit generalizability. Future research should prioritize head-to-head comparisons of RTX dosing regimens and explore biomarkers for personalized therapy.

Conclusion

This NMA provides a comprehensive evidence hierarchy for AIBD treatments, affirming rituximab’s central role in modern management. By integrating efficacy, safety, and steroid-sparing outcomes, the analysis supports tailored therapeutic strategies to optimize patient outcomes while minimizing treatment-related morbidity.

doi.org/10.1097/CM9.0000000000003446

Was this helpful?

0 / 0